Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 6,910,000 shares, a growth of 6.1% from the October 15th total of 6,510,000 shares. Based on an average daily trading volume, of 236,300 shares, the days-to-cover ratio is currently 29.2 days. Approximately 23.8% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Robert W. Baird lifted their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Stock Up 1.9 %

Shares of Enliven Therapeutics stock traded up $0.47 during trading on Tuesday, reaching $25.37. 120,277 shares of the company were exchanged, compared to its average volume of 259,536. Enliven Therapeutics has a twelve month low of $9.80 and a twelve month high of $30.03. The business has a 50-day moving average price of $26.32 and a 200-day moving average price of $24.05. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -13.16 and a beta of 1.08.

Insider Buying and Selling

In other news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $22.89, for a total value of $274,680.00. Following the completion of the sale, the chief executive officer now directly owns 1,049,255 shares of the company’s stock, valued at approximately $24,017,446.95. This trade represents a 1.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 847 shares of Enliven Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $25,410.00. Following the completion of the sale, the insider now directly owns 1,015,188 shares of the company’s stock, valued at $30,455,640. This trade represents a 0.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,195 shares of company stock worth $4,091,454 in the last 90 days. 29.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in ELVN. Quest Partners LLC grew its stake in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Enliven Therapeutics during the first quarter worth about $167,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after purchasing an additional 3,559 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $256,000. Finally, Verition Fund Management LLC acquired a new position in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $271,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.